摘要
目的探讨检测血清促甲状腺索受体抗体（TRAb）水平在甲状腺疾病诊治中的意义。方法分别检测343例甲状腺疾病患者（分为Graves病初诊组、Graves病缓解组、Graves病复发组、桥本病组和其他甲状腺疾病组）及68例正常者（正常对照组）的血清TRAb、游离三碘甲状腺原氨酸（FL）、游离甲状腺索（FT4）及甲状腺球蛋白抗体（TGAb）、甲状腺过氧化物酶抗体（TPOAb）水平。结果血清TRAb水平及阳性率在Graves病初诊组、Graves病缓解组、Graves病复发组及桥本病组均明显高于正常对照组；Graves病初诊组和Graves病复发组明显高于Graves病缓解组；Graves病初诊组、Graves病缓解组及Graves病复发组的血清TRAb与FT3、FT4间均无相关性。结论对血清TRAb水平的检测在甲状腺疾病特别是Graves病的诊治中具有重要意义，但其水平的高低却不能反映Graves病的病情轻重。
Objective To investigate the clinical significance of measurement of serum throid-stimulating hormone receptor antiboby （TRAb） levels in diagnosis and therapy of patients with thyroid disease. Method The levels of serum TRAb, FT3, FT4 and titrations of TGAb, thyroid-stimulating hormone receptor antiboby （TPOAb） were measured in 343 patients with thyroid disease as well as in 68 normal people. Resuits The average levels and positive rates of serum TRAb were significantly higher in patients with Graves disease （including untreated group, modified group and relapsing group） and Hashimoto disease than those in control group, and the untreated group and relapsing group were significantly higher than that in the modified group in level and positive rate of TRAb. There were no correlations between serum TRAb levels and FT3, FT4 levels in patients with.Graves disease, and titrations of TGAb, TPOAb in patients with Hashimoto disease. Conclusions There is important significance to measure the serum TRAb level in diagnosis and therapy of autoimmune thyroid diseases, especially to Graves disease, but the serum TRAb level can＇t reflect the severity of Graves disease.
出处
《中国医师进修杂志（内科版）》
2007年第1期40-42,共3页
Chinese Journal of Postgraduates of Medicine
